Rhythm Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RYTM)

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RYTM shares.
View RYTM analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued twelve-month price objectives for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $56.00. On average, they anticipate the company's share price to reach $37.71 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts.

Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has increased by 16.2% and is now trading at $33.83.
View the best growth stocks for 2023 here.

Rhythm Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 9,410,000 shares, a drop of 19.2% from the October 31st total of 11,650,000 shares. Based on an average daily volume of 571,000 shares, the days-to-cover ratio is currently 16.5 days.
View Rhythm Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our RYTM earnings forecast.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). The company earned $22.50 million during the quarter, compared to analysts' expectations of $22.18 million. Rhythm Pharmaceuticals had a negative net margin of 299.33% and a negative trailing twelve-month return on equity of 85.92%. Rhythm Pharmaceuticals's revenue was up 425.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.79) EPS.

ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (13.99%), Polar Capital Holdings Plc (4.23%), Federated Hermes Inc. (3.96%), FMR LLC (1.47%), Northern Trust Corp (0.85%) and Assenagon Asset Management S.A. (0.72%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, Ra Capital Management, LP, William T Roberts and Yann Mazabraud.
View institutional ownership trends.

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.